Published in Cancer Res on February 01, 2005
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
The clinical implications of medulloblastoma subgroups. Nat Rev Neurol (2012) 2.12
EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell (2014) 2.06
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Medulloblastoma stem cells. J Clin Oncol (2008) 1.71
Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics (2009) 1.40
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A (2012) 1.13
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol (2008) 1.12
Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol (2010) 1.09
RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer (2009) 1.08
Temporal and spatial delineation of mouse Otx2 functions by conditional self-knockout. EMBO Rep (2006) 1.03
Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia (2010) 1.03
The oncogenic role of Yin Yang 1. Crit Rev Oncog (2011) 1.02
A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer (2009) 1.02
Molecular diagnostics in embryonal brain tumors. Brain Pathol (2011) 1.00
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
Aggressive infantile embryonal tumors. J Child Neurol (2008) 0.96
Expression of the homeobox genes OTX2 and OTX1 in the early developing human brain. J Histochem Cytochem (2010) 0.96
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro Oncol (2010) 0.89
Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res (2009) 0.87
Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol (2010) 0.86
Cancer reduces transcriptome specialization. PLoS One (2010) 0.85
Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. PLoS One (2011) 0.85
Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer (2011) 0.84
Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. Am J Pathol (2009) 0.84
Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells. Biochem Pharmacol (2013) 0.83
RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma. Mol Cells (2014) 0.82
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines. J Exp Clin Cancer Res (2013) 0.81
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discov (2015) 0.79
Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Arch Pathol Lab Med (2011) 0.78
OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells. Dis Model Mech (2015) 0.78
The role of mutation in the new cancer paradigm. Cancer Cell Int (2005) 0.78
Fenretinide: a novel treatment for endometrial cancer. PLoS One (2014) 0.76
Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathol Appl Neurobiol (2014) 0.75
Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma. PLoS One (2014) 0.75
OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov (2017) 0.75
OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas. Eur J Histochem (2017) 0.75
Periconceptional folate consumption is associated with neonatal DNA methylation modifications in neural crest regulatory and cancer development genes. Epigenetics (2015) 0.75
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. J Exp Clin Cancer Res (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Cancer genome landscapes. Science (2013) 25.33
International network of cancer genome projects. Nature (2010) 20.35
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol (2007) 6.43
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
The antisense transcriptomes of human cells. Science (2008) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Aneuploidy and cancer. Nature (2004) 5.61
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57